{"Clinical Trial ID": "NCT00033514", "Intervention": ["INTERVENTION 1:", "1 Plus Phase 2", "Trastuzumab: Day 1 4mg/kg IV 2 mg/kg IV per week.", "erlotinib hydrochloride: 150 mg daily."], "Eligibility": ["Incorporation criteria:", "Women over 18 years of age", "Histologically documented metastatic breast cancer", "\u00b7 HER2 positive using in situ fluorescence hybridization (FISH)", "For Phase I, patients who have already received treatment for their metastatic disease are allowed to participate.", "For the Phase II part of the study, patients must have a measurable disease (> 2 cm; > 1 cm on spiral scan)", "The Eastern Cooperative Oncology Group (ECOG) achieved a yield of 0 to 2", "A life expectancy of > 3 months", "Use of effective contraceptives", "- Exclusion criteria:", "For Phase II, prior cytotoxic chemotherapy and/or prior Herceptin for metastatic disease are allowed."], "Results": ["Performance measures:", "The objective response rate as defined as a stable disease or the rate of complete and partial responses determined on two consecutive occasions greater than or equal to 4 weeks with the exception.", "Complete reply:", "The disappearance of all signs of cancer in response to treatment. This does not always mean that cancer has been cured. Also called complete remission.", "Partial reply:", "A decrease in the size of a tumour, or in the extent of cancer in the body, in response to treatment, also called partial remission.", "Time limit: 5 years", "Results 1:", "Title of arm/group: Treatment Phase 1 Plus Phase 2", "Description of the arm/group: trastuzumab: Day 1 4mg/kg IV 2 mg/kg IV weekly.", "erlotinib hydrochloride: 150 mg daily.", "Total number of participants analysed: 12", "Type of measurement: Number", "Unit of measure: participants Partial reply: 4", "Stable disease: 1"], "Adverse Events": ["Undesirable Events 1:", "Total: 16/27 (59.26 per cent)", "Dyspnoea * 6/27 (22.22%)", "* 1/27 (3.70%)", "* [1]1/27 (3.70%)", "- LVEF below the lower limit of normal * 2/27 (7.4%)", "* 1/27 (3.70%)", "Dehydration/pain management * 1/27 (3.70%)", "Gastroenteritis * [2]1/27 (3.70%)", "* 2/27 (7.41%)"]}